MedTrace Logo

Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

NCT01869491 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1107

Last updated 2025-05-08

Study results available
· View outcomes & findings →

Summary

This study is being conducted to provide evidence that Compound Sodium Alginate Double Action Chewable Tablets are effective in managing the symptoms of heartburn, acid regurgitation and dyspepsia in patients with Gastroesophageal Reflux Disease (GERD).

Conditions

  • Gastroesophageal Reflux Disease
  • Dyspepsia

Interventions

DRUG

Compound Sodium Alginate Double Action Chewable Tablets

2 tablets four times daily

DRUG

Matching placebo tablets

2 tablets four times daily

Sponsors & Collaborators

  • Reckitt Benckiser Healthcare (UK) Limited

    lead INDUSTRY

Principal Investigators

  • Yuan Yaozong, MD, PhD · Shanghai Jiao Tong University, School of Medicine, Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-05
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01869491 on ClinicalTrials.gov